Table 3. . Summary of key stereotactic radiosurgery studies.
| Study | No. of patients (% melanoma) | SRS treatment (n) | Mean marginal dose (range), Gy | Local control (%) | Median overall survival (months) | Ref. |
|---|---|---|---|---|---|---|
| Grob et al. | 35 (100) | GK | NR (14–40) | 98.2† | 1 BM: 22.0 1 BM + extracranial disease: 7.5 Multiple BMs: 4.0 |
[41] |
| Mori et al. | 60 (100) | GK salvage (12) WBRT + GK (36) GK alone (12) |
16.4 (10–20) | 90 | 7.0 | [42] |
| Herfarth et al. | 64 (100) | Linac 18 (10–24) Linac salvage (30) |
20 (15–22) | 81‡ | 10.6 | [43] |
| Selek et al. | 103 (100) | WBRT + Linac (12) Linac alone (61) |
18 (10–24) | 49‡ | 25.2%‡ | [44] |
| Chang et al. | 189 (54) | Linac WBRT + GK (110) |
18 (10–24) | 47‡ | 6.7 | [45] |
| Mathieu et al. | 244 (100) | GK alone (115) Postop (53) Prior SRS (2) |
17.4 (10–22) | 86.2 | 5.3 | [46] |
†At 3 months;
‡At 1 year.
BM: Brain metastasis; GK: Gamma knife; Linac: Linear accelerator; NR: Not reported; postop: Postoperative; SRS: Stereotactic radiosurgery.